Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Inclusion Criteria: * Adult ≥18 years * Infection with HCV genotype 4, confirmed by detectable HCV RNA ≥ 1000 IU/ml at pre-inclusion * Non-responders to a prior treatment with pegylated Interferon and Ribavirin, with non-response being defined as follows: * Null-response: reduction of less than 2 log10 IU/ml of HCV viral load between D0 of the treatment and week 12 * Partial response: reduction of at least 2 log10 IU/ml of HCV viral load between D0 of the treatment and week 12 but detectable HCV RNA at week 12 and week 24 and without an undetectable viral load by the end of treatment * Anti-HCV treatment discontinued for at least the last 3 months * Fibrosis at any stage, with documentation of the presence or absence of cirrhosis at the pre-inclusion visit: * history of liver biopsy showing cirrhosis lesions (METAVIR F4), at any time in the patient's history, and/or * good quality (length ≥ 15 mm and ≥ 6 portal spaces) liver puncture biopsy from less than 18 months to establish the METAVIR, and/or * hepatic impulse elastometry (Fibroscan®) from less than 6 months and of good quality (at least 10 measurements on an incidence with an IQR of less than 30% of the mean elastometry measured and a success rate of 60%) * Body weight ≥ 40 kg and ≤125 kg * Men and women of child-bearing age and their heterosexual partners must use two adequate contraceptions from 1 month before initiation of treatment up to 7 months after the end of treatment for men and up to 4 months aft…